1
|
Bustin SA. RT-qPCR Testing and Performance Metrics in the COVID-19 Era. Int J Mol Sci 2024; 25:9326. [PMID: 39273275 PMCID: PMC11394961 DOI: 10.3390/ijms25179326] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/06/2024] [Revised: 08/23/2024] [Accepted: 08/26/2024] [Indexed: 09/15/2024] Open
Abstract
The COVID-19 pandemic highlighted the crucial role of diagnostic testing in managing infectious diseases, particularly through the use of reverse transcription-quantitative polymerase chain reaction (RT-qPCR) tests. RT-qPCR has been pivotal in detecting and quantifying viral RNA, enabling the identification and management of SARS-CoV-2 infections. However, despite its widespread use, there remains a notable gap in understanding fundamental diagnostic metrics such as sensitivity and specificity among many scientists and healthcare practitioners. This gap is not merely academic; it has profound implications for interpreting test results, making public health decisions, and affecting patient outcomes. This review aims to clarify the distinctions between laboratory- and field-based metrics in the context of RT-qPCR testing for SARS-CoV-2 and summarise the global efforts that led to the development and optimisation of these tests during the pandemic. It is intended to enhance the understanding of these fundamental concepts among scientists and healthcare professionals who may not be familiar with the nuances of diagnostic test evaluation. Such knowledge is crucial for accurately interpreting test results, making informed public health decisions, and ultimately managing infectious disease outbreaks more effectively.
Collapse
Affiliation(s)
- Stephen A Bustin
- Medical Technology Research Centre, Anglia Ruskin University, Chelmsford CM1 1SQ, UK
| |
Collapse
|
2
|
Feddema JJ, Fernald KDS, Keijser BJF, Kieboom J, van de Burgwal LHM. Commercial Opportunity or Addressing Unmet Needs-Loop-Mediated Isothermal Amplification (LAMP) as the Future of Rapid Diagnostic Testing? Diagnostics (Basel) 2024; 14:1845. [PMID: 39272630 PMCID: PMC11394392 DOI: 10.3390/diagnostics14171845] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/11/2024] [Revised: 08/01/2024] [Accepted: 08/14/2024] [Indexed: 09/15/2024] Open
Abstract
Loop-Mediated Isothermal Amplification (LAMP) technology is emerging as a rapid pathogen testing method, potentially challenging the RT-PCR "gold standard". Despite recent advancements, LAMP's widespread adoption remains limited. This study provides a comprehensive market overview and assesses future growth prospects to aid stakeholders in strategic decision-making and policy formulation. Using a dataset of 1134 LAMP patent documents, we analyzed lifecycle and geographic distribution, applicant profiles, CPC code classifications, and patent claims. Additionally, we examined clinical developments from 21 curated clinical trials, focusing on trends, geographic engagement, sponsor types, and the conditions and pathogens investigated. Our analysis highlights LAMP's potential as a promising rapid pathogen testing alternative, especially in resource-limited areas. It also reveals a gap between clinical research, which targets bacterial and parasitic diseases like malaria, leishmaniasis, and tuberculosis, and basic research and commercial efforts that prioritize viral diseases such as SARS-CoV-2 and influenza. European stakeholders emphasize the societal impact of addressing unmet needs in resource-limited areas, while American and Asian organizations focus more on research, innovation, and commercialization.
Collapse
Affiliation(s)
- Jelle J Feddema
- Athena Institute, Vrije Universiteit Amsterdam, De Boelelaan 1085, 1081 HV Amsterdam, The Netherlands
| | - Kenneth D S Fernald
- Athena Institute, Vrije Universiteit Amsterdam, De Boelelaan 1085, 1081 HV Amsterdam, The Netherlands
| | - Bart J F Keijser
- TNO Healthy Living and Work, Microbiology and Systems Biology, Sylviusweg 71, 2333 BE Leiden, The Netherlands
| | - Jasper Kieboom
- TNO Healthy Living and Work, Microbiology and Systems Biology, Sylviusweg 71, 2333 BE Leiden, The Netherlands
| | - Linda H M van de Burgwal
- Athena Institute, Vrije Universiteit Amsterdam, De Boelelaan 1085, 1081 HV Amsterdam, The Netherlands
| |
Collapse
|
3
|
Garg R, Prasad D. Enhanced pyrophosphate detection: Utilizing oPD-derived carbon dots and Fe 3+ interactions in a paper strip biosensor. Biochem Biophys Res Commun 2024; 739:150577. [PMID: 39181072 DOI: 10.1016/j.bbrc.2024.150577] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/19/2024] [Revised: 07/17/2024] [Accepted: 08/20/2024] [Indexed: 08/27/2024]
Abstract
The development of portable, cost-effective, and straightforward DNA biosensors holds immense importance in various fields, including healthcare, environmental monitoring, and food safety. This study contributes to the objective by introducing an innovative approach for synthesizing carbon dots (Cdots) with high quantum yield (QY) and remarkable selectivity for Fe3+ ions. Utilizing o-phenylenediamine as a precursor, the study achieved a straightforward and environmentally friendly synthesis method, enabling the efficient detachment of metal ions from the Cdot surface upon introducing pyrophosphate (PPi). The presence of surface hydroxyl and amino groups facilitated specific Fe3+ recognition. Employing D-optimal response surface methodology, the study optimized Cdot synthesis parameters, identifying temperature and heating time as critical factors influencing QY. Statistical analysis confirmed the model's reliability, predicting maximum QY of 48.8 % with minimal deviation from experimental results. Characterization studies revealed the amorphous nature of Cdots through HR-TEM, XRD, and FTIR analysis. Furthermore, the proposed LAMP/PPi biosensing technique demonstrated higher sensitivity, specificity, and repeatability, with negligible interference from common anions and efficacy across varying pH levels. The limit of detection (LOD) of 0.079 (±0.01) μM and the detection range of 0.1 μM-2 mM underscore the biosensor's practical utility. This study highlights a promising direction for developing paper-based LAMP/PPi biosensors with potential diagnostics and environmental monitoring applications. Significantly, the biosensing technique is applicable to any DNA amplification method generating pyrophosphate (PPi) as a by-product.
Collapse
Affiliation(s)
- Rishabh Garg
- Department of Bioengineering and Biotechnology, Birla Institute of Technology, Mesra, Jharkhand, 835215, India
| | - Dinesh Prasad
- Department of Bioengineering and Biotechnology, Birla Institute of Technology, Mesra, Jharkhand, 835215, India.
| |
Collapse
|
4
|
Li P, Zhang H, Yang Z, Li Y, Huang M, Yang L, Zhang X. Rapid fluorescent nucleic acid sensing with ultra-thin gold nanosheets. Anal Chim Acta 2024; 1317:342872. [PMID: 39030016 DOI: 10.1016/j.aca.2024.342872] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/20/2024] [Revised: 05/31/2024] [Accepted: 06/13/2024] [Indexed: 07/21/2024]
Abstract
Fluorescently labeled DNA oligonucleotides and gold nanospheres have been frequently utilized in biosensors, providing efficient nucleic acid detection. Nevertheless, the restricted loading capacity of gold nanospheres undermines overall sensitivity. In this study, we employed four-atom-thick ultrathin gold nanosheets (AuNSs), utilizing a "pre-mix model" for rapid target nucleic acid detection. In this approach, fluorescently labeled DNA probes were pre-incubated with the target nucleic acid, followed by the addition of AuNSs for probe adsorption and fluorescence quenching. With the developed method, we efficiently and rapidly detected the SARS-CoV-2 N gene sequence within 30 min, involving a brief 15-min target pre-incubation and a subsequent 15-min adsorption of free probes and fluorescence quenching by AuNSs. This method exhibited heightened sensitivity compared to gold nanospheres, boasting a limit of detection (LOD) of 0.808 nM. Furthermore, exceptional recovery was achieved in simulated biological samples. The study introduces an effective strategy for nucleic acid sensing characterized by rapidity, heightened sensitivity, ease of operation, and robustness. These findings encourage further development of rapid biomarker sensing methods employing 2D nanomaterials.
Collapse
Affiliation(s)
- Peiyin Li
- School of Pharmacy, Shenzhen University Medical School, Shenzhen University, Shenzhen, 518055, China
| | - Huiyang Zhang
- School of Pharmacy, Shenzhen University Medical School, Shenzhen University, Shenzhen, 518055, China
| | - Zhenyu Yang
- School of Biomedical Engineering, Marshall Laboratory of Biomedical Engineering, Shenzhen University Medical School, Shenzhen University, Guangdong, 518055, China
| | - Yiling Li
- School of Pharmacy, Shenzhen University Medical School, Shenzhen University, Shenzhen, 518055, China
| | - Manli Huang
- School of Pharmacy, Shenzhen University Medical School, Shenzhen University, Shenzhen, 518055, China
| | - Lingzhi Yang
- School of Pharmacy, Shenzhen University Medical School, Shenzhen University, Shenzhen, 518055, China.
| | - Xueji Zhang
- School of Biomedical Engineering, Marshall Laboratory of Biomedical Engineering, Shenzhen University Medical School, Shenzhen University, Guangdong, 518055, China
| |
Collapse
|
5
|
Harris DT, Ingraham N, Badowski M. Comparison of Manual versus Automated SARS-CoV-2 Rapid Antigen Testing in Asymptomatic Individuals. J Clin Med 2023; 12:7146. [PMID: 38002757 PMCID: PMC10672191 DOI: 10.3390/jcm12227146] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/09/2023] [Revised: 11/13/2023] [Accepted: 11/15/2023] [Indexed: 11/26/2023] Open
Abstract
The SARS-CoV-2 pandemic has infected more than 770 M people and killed more than 6.9 M persons worldwide. In the USA, as of August 2023, it has infected more than 103 M people while causing more than 1.1 M deaths. During a pandemic, it is necessary to rapidly identify those individuals infected with the virus so that disease transmission can be stopped. We examined the sensitivity of the Quidel Rapid Antigen test on the manual Sofia 2 platform and the Beckman-Coulter antigen test on the automated DxI-800 system for use in screening asymptomatic individuals at the University of Arizona from March through May 2021. A total of 378 asymptomatic subjects along with 176 validation sets of samples in 23 independent experiments were assessed in side-by-side antigen testing using both assays. Nasal swabs and saliva were used as viral sources. Manual testing (Quidel) was compared with automated testing (Beckman) methods for cost and efficiency. Limit dilution of viral antigen spiked samples was performed to determine sensitivity to antigen load by the tests. The results between the two tests were found to be concordant. Both tests were comparable in terms of detecting low numbers of positive subjects in the asymptomatic population. A concordance of 98% was observed between the two tests. Experiments also demonstrated that saliva specimens were an acceptable viral source and produced comparable results for each test. Overall, the two methods were interchangeable.
Collapse
Affiliation(s)
- David T. Harris
- University of Arizona Health Sciences Biorepository, Tucson, AZ 85724, USA; (N.I.); (M.B.)
- Department of Immunobiology & Medicine, The University of Arizona, Tucson, AZ 85724, USA
- Biorepository, The University of Arizona, AHSC 6122, 1501 N Campbell Ave, P.O. Box 245221, Tucson, AZ 85724, USA
| | - Nicole Ingraham
- University of Arizona Health Sciences Biorepository, Tucson, AZ 85724, USA; (N.I.); (M.B.)
| | - Michael Badowski
- University of Arizona Health Sciences Biorepository, Tucson, AZ 85724, USA; (N.I.); (M.B.)
| |
Collapse
|
6
|
Otshudiema JO, Folefack GLT, Nsio JM, Kakema CH, Minikulu L, Bafuana A, Kosianza JB, Mfumu AK, Nkwembe E, Munyeku-Bazitama Y, Makiala-Mandanda S, Guinko N, Mbuyi G, Tshilumbu JMK, Saidi GN, Umba-di-Masiala MS, Ebondo AK, Mutonj JJ, Kalombo S, Kabeya J, Mawanda TK, Bile FN, Kasereka GK, Mbala-Kingebeni P, Ahuka-Mundeke S, Karamagi HC, Fai KN, Djiguimde AP. Community-based COVID-19 active case finding and rapid response in the Democratic Republic of the Congo: Improving case detection and response. PLoS One 2023; 18:e0278251. [PMID: 37200322 PMCID: PMC10194859 DOI: 10.1371/journal.pone.0278251] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/11/2022] [Accepted: 04/25/2023] [Indexed: 05/20/2023] Open
Abstract
A community-based coronavirus disease (COVID-19) active case-finding strategy using an antigen-detecting rapid diagnostic test (Ag-RDT) was implemented in the Democratic Republic of Congo (DRC) to enhance COVID-19 case detection. With this pilot community-based active case finding and response program that was designed as a clinical, prospective testing performance, and implementation study, we aimed to identify insights to improve community diagnosis and rapid response to COVID-19. This pilot study was modeled on the DRC's National COVID-19 Response Plan and the COVID-19 Ag-RDT screening algorithm defined by the World Health Organization (WHO), with case findings implemented in 259 health areas, 39 health zones, and 9 provinces. In each health area, a 7-member interdisciplinary field team tested the close contacts (ring strategy) and applied preventive and control measures to each confirmed case. The COVID-19 testing capacity increased from 0.3 tests per 10,000 inhabitants per week in the first wave to 0.4, 1.6, and 2.2 in the second, third, and fourth waves, respectively. From January to November 2021, this capacity increase contributed to an average of 10.5% of COVID-19 tests in the DRC, with 7,110 positive Ag-RDT results for 40,226 suspected cases and close contacts who were tested (53.6% female, median age: 37 years [interquartile range: 26.0-50.0)]. Overall, 79.7% (n = 32,071) of the participants were symptomatic and 7.6% (n = 3,073) had comorbidities. The Ag-RDT sensitivity and specificity were 55.5% and 99.0%, respectively, based on reverse transcription polymerase chain reaction analysis, and there was substantial agreement between the tests (k = 0.63). Despite its limited sensitivity, the Ag-RDT has improved COVID-19 testing capacity, enabling earlier detection, isolation, and treatment of COVID-19 cases. Our findings support the community testing of suspected cases and asymptomatic close contacts of confirmed cases to reduce disease spread and virus transmission.
Collapse
Affiliation(s)
| | | | - Justus M. Nsio
- COVID-19 Response, Ministry of Health, Kinshasa, Democratic Republic of the Congo
| | - Cathy H. Kakema
- COVID-19 Response, World Health Organization, Kinshasa, Democratic Republic of the Congo
| | - Luigino Minikulu
- COVID-19 Response, Ministry of Health, Kinshasa, Democratic Republic of the Congo
| | - Aimé Bafuana
- COVID-19 Response, Ministry of Health, Kinshasa, Democratic Republic of the Congo
| | - Joel B. Kosianza
- COVID-19 Response, World Health Organization, Kinshasa, Democratic Republic of the Congo
| | - Antoine K. Mfumu
- COVID-19 Response, World Health Organization, Kinshasa, Democratic Republic of the Congo
| | - Edith Nkwembe
- COVID-19 Laboratory and Epidemiology Team, National Institute of Biomedical Research, Kinshasa, Democratic Republic of the Congo
| | - Yannick Munyeku-Bazitama
- COVID-19 Laboratory and Epidemiology Team, National Institute of Biomedical Research, Kinshasa, Democratic Republic of the Congo
| | - Sheila Makiala-Mandanda
- COVID-19 Laboratory and Epidemiology Team, National Institute of Biomedical Research, Kinshasa, Democratic Republic of the Congo
| | - Noé Guinko
- COVID-19 Response, World Health Organization, Kinshasa, Democratic Republic of the Congo
| | - Gisèle Mbuyi
- COVID-19 Response, Ministry of Health, Kinshasa, Democratic Republic of the Congo
| | | | - Guy N. Saidi
- COVID-19 Response, World Health Organization, Kinshasa, Democratic Republic of the Congo
| | | | - Amos K. Ebondo
- COVID-19 Response, World Health Organization, Kinshasa, Democratic Republic of the Congo
| | - Jean-Jacques Mutonj
- COVID-19 Response, World Health Organization, Kinshasa, Democratic Republic of the Congo
| | - Serge Kalombo
- COVID-19 Response, World Health Organization, Kinshasa, Democratic Republic of the Congo
| | - Jad Kabeya
- COVID-19 Response, World Health Organization, Kinshasa, Democratic Republic of the Congo
| | - Taty K. Mawanda
- COVID-19 Response, World Health Organization, Kinshasa, Democratic Republic of the Congo
| | - Faustin N. Bile
- COVID-19 Response, World Health Organization, Kinshasa, Democratic Republic of the Congo
| | - Gaby K. Kasereka
- COVID-19 Response, World Health Organization, Kinshasa, Democratic Republic of the Congo
| | - Placide Mbala-Kingebeni
- COVID-19 Laboratory and Epidemiology Team, National Institute of Biomedical Research, Kinshasa, Democratic Republic of the Congo
| | - Steve Ahuka-Mundeke
- COVID-19 Laboratory and Epidemiology Team, National Institute of Biomedical Research, Kinshasa, Democratic Republic of the Congo
| | - Humphrey Cyprian Karamagi
- Data Analytics and Knowledge Management, World Health Organization Regional Office for Africa, Brazzaville, Democratic Republic of Congo
| | | | | |
Collapse
|
7
|
Mareti E, Vavoulidis E, Papanastasiou A, Maretis T, Tsampazis N, Margioula-Siarkou C, Chatzinikolaou F, Giasari S, Nasioutziki M, Daniilidis A, Zepiridis L, Dinas K. Evaluating the potential role of human papilloma virus infection in breast carcinogenesis via real-time polymerase chain reaction analyzes of breast fine needle aspiration samples from Greek patients. Diagn Cytopathol 2023. [PMID: 36939123 DOI: 10.1002/dc.25130] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/01/2023] [Accepted: 03/07/2023] [Indexed: 03/21/2023]
Abstract
BACKGROUND Human papilloma virus (HPV), in addition to its known clinical contribution to cervical cancer is probably actively involved in the development of breast tumors in various populations worldwide. Predominant HPV types in breast cancer patients vary geographically. The present study further examines HPV incidence in Greece, based on molecular analysis of clinical cytological samples. METHODS Greek patient fine needle aspiration (FNA) biopsy samples were examined using RT-PCR and immunohistological staining. FNA biopsy samples were collected from 114 female patients, diagnosed between the years 2018 and 2021, 57 with C5 diagnosed breast cancer lesions and 57 diagnosed with benign diseases. RESULTS A total of three different HPV types were identified within the patient sample. HPV-39 was found only in the control group, in 1.8% of patients, while HPV-59 was present in both control and study groups in 1.8% and 3.5% respectively. HPV-16, on the other hand, was present only in the study group in 12.3% of cases. HPV type presence was statistically differentiated between histological groups. HPV-16 was exclusively in IDC, HPV-39 was present in one cyst diagnosed sample and HPV-59 was present in 3 samples that included fibroadenoma, IDC and LN diagnosis. CONCLUSION More international comparative studies are required to investigate population differences and HPV genotype distribution to offer definite answers to the effect that certain HPV types might have a role in breast cancer, as this study also supports, albeit in a cofactory role.
Collapse
Affiliation(s)
- Evangelia Mareti
- 2nd Department of Obstetrics and Gynecology, School of Medicine, Aristotle University of Thessaloniki, Hippokration General Hospital, Thessaloniki, Greece.,Laboratory of Gynecologic Oncology, 2nd Department of Obstetrics and Gynecology, School of Medicine, Aristotle University of Thessaloniki, Hippokration General Hospital, Thessaloniki, Greece
| | - Eleftherios Vavoulidis
- 2nd Department of Obstetrics and Gynecology, School of Medicine, Aristotle University of Thessaloniki, Hippokration General Hospital, Thessaloniki, Greece.,Laboratory of Gynecologic Oncology, 2nd Department of Obstetrics and Gynecology, School of Medicine, Aristotle University of Thessaloniki, Hippokration General Hospital, Thessaloniki, Greece
| | - Anastasios Papanastasiou
- 2nd Department of Obstetrics and Gynecology, School of Medicine, Aristotle University of Thessaloniki, Hippokration General Hospital, Thessaloniki, Greece
| | - Theodoros Maretis
- 2nd Department of Obstetrics and Gynecology, School of Medicine, Aristotle University of Thessaloniki, Hippokration General Hospital, Thessaloniki, Greece
| | - Nikolaos Tsampazis
- 2nd Department of Obstetrics and Gynecology, School of Medicine, Aristotle University of Thessaloniki, Hippokration General Hospital, Thessaloniki, Greece.,Laboratory of Gynecologic Oncology, 2nd Department of Obstetrics and Gynecology, School of Medicine, Aristotle University of Thessaloniki, Hippokration General Hospital, Thessaloniki, Greece
| | - Chrysoula Margioula-Siarkou
- 2nd Department of Obstetrics and Gynecology, School of Medicine, Aristotle University of Thessaloniki, Hippokration General Hospital, Thessaloniki, Greece.,Laboratory of Gynecologic Oncology, 2nd Department of Obstetrics and Gynecology, School of Medicine, Aristotle University of Thessaloniki, Hippokration General Hospital, Thessaloniki, Greece
| | - Fotios Chatzinikolaou
- Laboratory of Forensic Medicine and Toxicology, School of Medicine, Faculty of Health Sciences, Aristotle University, Thessaloniki, Greece
| | - Sofia Giasari
- 2nd Department of Obstetrics and Gynecology, School of Medicine, Aristotle University of Thessaloniki, Hippokration General Hospital, Thessaloniki, Greece
| | - Maria Nasioutziki
- 2nd Department of Obstetrics and Gynecology, School of Medicine, Aristotle University of Thessaloniki, Hippokration General Hospital, Thessaloniki, Greece
| | - Angelos Daniilidis
- 2nd Department of Obstetrics and Gynecology, School of Medicine, Aristotle University of Thessaloniki, Hippokration General Hospital, Thessaloniki, Greece.,Laboratory of Gynecologic Oncology, 2nd Department of Obstetrics and Gynecology, School of Medicine, Aristotle University of Thessaloniki, Hippokration General Hospital, Thessaloniki, Greece
| | - Leonidas Zepiridis
- 1st Department of Obstetrics & Gynecology, School of Medicine, Aristotle University of Thessaloniki, Papageorgiou General Hospital, Thessaloniki, Greece
| | - Konstantinos Dinas
- 2nd Department of Obstetrics and Gynecology, School of Medicine, Aristotle University of Thessaloniki, Hippokration General Hospital, Thessaloniki, Greece.,Laboratory of Gynecologic Oncology, 2nd Department of Obstetrics and Gynecology, School of Medicine, Aristotle University of Thessaloniki, Hippokration General Hospital, Thessaloniki, Greece
| |
Collapse
|
8
|
Luo J, Zhang J, Tang HT, Wong HK, Ma Y, Xie D, Peng B, Lyu A, Cheung CH, Bian Z. Weekly symptom profiles of nonhospitalized individuals infected with SARS-CoV-2 during the Omicron outbreak in Hong Kong: A retrospective observational study from a telemedicine center. J Med Virol 2023; 95:e28447. [PMID: 36583471 PMCID: PMC9880749 DOI: 10.1002/jmv.28447] [Citation(s) in RCA: 3] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/16/2022] [Revised: 12/21/2022] [Accepted: 12/28/2022] [Indexed: 12/31/2022]
Abstract
Omicron BA.2.2 is the dominant variant in the Hong Kong outbreak since December 31, 2021. There is no study reporting the weekly symptom profile after infection. In this retrospective study, participants who tested positive for SARS-CoV-2 after December 31, 2021, and registered in the telemedicine system between March 14 and May 6, 2022, were analyzed. Among registered 12 950 self-quarantined COVID-19-positive patients, 11 776 symptomatic patients were included for weekly symptom profile analysis. A total of 4718 (40.1%) patients reported symptoms in the first week after a positive test, 2501 (21.2%) in the second week, 1498 (12.7%) in the third week, 1048 (8.9%) in the fourth week, and 2011 (17.1%) in over 4 weeks. Cough was the most common symptom in all participants. Patients in the first week had higher odds of reporting fever (0.206, 95% confidence interval [CI]: 0.161-0.263, p < 0.001) and sore throat (0.228, 95% CI: 0.208-0.252, p < 0.001). Patients in over 4 weeks had higher odds of reporting fatigue (1.263, 95% CI: 1.139-1.402, p < 0.001). Further, having at least two vaccine doses linked to lower odds of having fever (0.675, 95% CI: 0.562-0.811, p < 0.001), but not associated with the presence of cough and fatigue. Diabetic patients had higher odds of reporting diarrhea (1.637, 95% CI: 1.351-1.982, p < 0.001). Symptoms from Omicron infection may last for more than 4 weeks and symptom profiles vary from week to week. Vaccination and comorbidity affect the symptom profiles.
Collapse
Affiliation(s)
- Jingyuan Luo
- Hong Kong Chinese Medicine Clinical Study Centre, School of Chinese MedicineHong Kong Baptist UniversityHong Kong SARChina,Centre for Chinese Herbal Medicine Drug DevelopmentHong Kong Baptist UniversityHong Kong SARChina
| | - Jialing Zhang
- Hong Kong Chinese Medicine Clinical Study Centre, School of Chinese MedicineHong Kong Baptist UniversityHong Kong SARChina,Centre for Chinese Herbal Medicine Drug DevelopmentHong Kong Baptist UniversityHong Kong SARChina
| | - Hiu To Tang
- School of Chinese MedicineHong Kong Baptist UniversityHong Kong SARChina
| | - Hoi Ki Wong
- School of Chinese MedicineHong Kong Baptist UniversityHong Kong SARChina
| | - Yanfang Ma
- School of Chinese MedicineHong Kong Baptist UniversityHong Kong SARChina
| | - Duoli Xie
- School of Chinese MedicineHong Kong Baptist UniversityHong Kong SARChina
| | - Bo Peng
- School of Chinese MedicineHong Kong Baptist UniversityHong Kong SARChina
| | - Aiping Lyu
- Hong Kong Chinese Medicine Clinical Study Centre, School of Chinese MedicineHong Kong Baptist UniversityHong Kong SARChina,School of Chinese MedicineHong Kong Baptist UniversityHong Kong SARChina
| | - Chun Hoi Cheung
- School of Chinese MedicineHong Kong Baptist UniversityHong Kong SARChina
| | - Zhaoxiang Bian
- Hong Kong Chinese Medicine Clinical Study Centre, School of Chinese MedicineHong Kong Baptist UniversityHong Kong SARChina,Centre for Chinese Herbal Medicine Drug DevelopmentHong Kong Baptist UniversityHong Kong SARChina,School of Chinese MedicineHong Kong Baptist UniversityHong Kong SARChina
| |
Collapse
|
9
|
Meena DS, Kumar B, Kachhwaha A, Kumar D, Khichar S, Bohra GK, Sharma A, Kothari N, Garg P, Sureka B, Banerjee M, Garg MK, Misra S. Comparison of clinical characteristics and outcome in RT-PCR positive and false-negative RT-PCR for COVID-19: A Retrospective analysis. LE INFEZIONI IN MEDICINA 2022; 30:403-411. [PMID: 36148177 PMCID: PMC9448311 DOI: 10.53854/liim-3003-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 04/04/2022] [Accepted: 06/08/2022] [Indexed: 06/16/2023]
Abstract
Cases with SARS-CoV-2 RT-PCR negative pneumonia are an understudied group with uncertainty remaining regarding their treatment approach. We aimed to compare the clinical and radiological characteristics of RT-PCR positive and clinically diagnosed RT-PCR negative COVID-19. This was a single-centre retrospective study conducted at a tertiary care hospital in Western India. All patients (age ≥18 years) with suspicion of COVID-19 with SARI (severe acute respiratory infections) who were subjected to RT-PCR testing (nasal/oropharyngeal swab) were included. Based on RTPCR results, patients were categorized and compared for demographic, clinical, and biochemical characteristics and outcomes. Out of 500 patients, 339 (67.8%) found RT-PCR positive. Except for the radiological findings, both groups differ in clinical presentation, disease severity (inflammatory markers), and outcome. RT-PCR-positive patients had raised ferritin, NLR (Neutrophil-Lymphocyte ratio), LDH, and high mortality compared to the swab-negative group. In-hospital mortality was also significantly high in RT-PCR positive group (HR=1.9, 95% CI=1.4-2.5, p=0.001). On multivariate analysis, NLR, ferritin, and d-dimer were the independent predictors of mortality in RT-PCR-positive (p=0.038, 0.054, and 0.023). At the same time, raised TLC (total leukocyte count) and procalcitonin were the risk factors for poor outcomes in RT-PCR-negative patients (p=0.041 and 0.038). We found significantly raised ferritin, NLR, and LDH levels and increased mortality in RT-PCR positive patients compared to RT-PCR negative. Incorporating clinical features, radiological, and biochemical parameters could be prudent while managing the RT-PCR-negative patients.
Collapse
Affiliation(s)
- Durga Shankar Meena
- Department of Internal Medicine, All India Institute of Medical Sciences, Jodhpur, Rajasthan, India
| | - Bharat Kumar
- Department of Internal Medicine, All India Institute of Medical Sciences, Jodhpur, Rajasthan, India
| | - Arjun Kachhwaha
- Department of Internal Medicine, All India Institute of Medical Sciences, Jodhpur, Rajasthan, India
| | - Deepak Kumar
- Department of Internal Medicine, All India Institute of Medical Sciences, Jodhpur, Rajasthan, India
| | - Satyendra Khichar
- Department of Internal Medicine, All India Institute of Medical Sciences, Jodhpur, Rajasthan, India
| | - Gopal Krishana Bohra
- Department of Internal Medicine, All India Institute of Medical Sciences, Jodhpur, Rajasthan, India
| | - Ankur Sharma
- Department of Trauma and Emergency (Anaesthesiology), All India Institute of Medical Sciences, Jodhpur, Rajasthan, India
| | - Nikhil Kothari
- Department of Anaesthesiology and Critical Care, All India Institute of Medical Sciences, Jodhpur, Rajasthan, India
| | - Pawan Garg
- Department of Diagnostic and Interventional Radiology, All India Institute of Medical Sciences, Jodhpur, Rajasthan, India
| | - Binit Sureka
- Department of Diagnostic and Interventional Radiology, All India Institute of Medical Sciences, Jodhpur, Rajasthan, India
| | - Mithu Banerjee
- Department of Biochemistry, All India Institute of Medical Sciences, Jodhpur, Rajasthan, India
| | - Mahendra Kumar Garg
- Department of Internal Medicine, All India Institute of Medical Sciences, Jodhpur, Rajasthan, India
| | - Sanjeev Misra
- All India Institute of Medical Sciences, Jodhpur, Rajasthan, India
| |
Collapse
|
10
|
Duncan DB, Mackett K, Ali MU, Yamamura D, Balion C. Performance of saliva compared with nasopharyngeal swab for diagnosis of COVID-19 by NAAT in cross-sectional studies: Systematic review and meta-analysis. Clin Biochem 2022; 117:84-93. [PMID: 35952732 PMCID: PMC9359767 DOI: 10.1016/j.clinbiochem.2022.08.004] [Citation(s) in RCA: 6] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/22/2022] [Revised: 07/14/2022] [Accepted: 08/05/2022] [Indexed: 11/03/2022]
Abstract
Nucleic acid amplification testing (NAAT) is the preferred method to diagnose coronavirus disease 2019 (COVID-19). Saliva has been suggested as an alternative to nasopharyngeal swabs (NPS), but previous systematic reviews were limited by the number and types of studies available. The objective of this systematic review and meta-analysis was to assess the diagnostic performance of saliva compared with NPS for COVID-19. We searched Ovid MEDLINE, Embase, Cochrane, and Scopus databases up to 24 April 2021 for studies that directly compared paired NPS and saliva specimens taken at the time of diagnosis. Meta-analysis was performed using an exact binomial rendition of the bivariate mixed-effects regression model. Risk of bias was assessed using the QUADAS-2 tool. Of 2683 records, we included 23 studies with 25 cohorts, comprising 11,582 paired specimens. A wide variety of NAAT assays and collection methods were used. Meta-analysis gave a pooled sensitivity of 87 % (95 % CI = 83-90 %) and specificity of 99 % (95 % CI = 98-99 %). Subgroup analyses showed the highest sensitivity when the suspected individual is tested in an outpatient setting and is symptomatic. Our results support the use of saliva NAAT as an alternative to NPS NAAT for the diagnosis of COVID-19.
Collapse
Affiliation(s)
- Donald Brody Duncan
- Department of Pathology and Molecular Medicine, McMaster University, Hamilton, Ontario L8S 4K1, Canada; Microbiology Department, Hamilton Regional Laboratory Medicine Program, Hamilton Health Sciences, Hamilton, Ontario L8L 2X2, Canada
| | - Katharine Mackett
- Department of Health Research Methods, Evidence and Impact, McMaster University, Hamilton, Ontario L8S 4K1, Canada
| | - Muhammad Usman Ali
- Department of Health Research Methods, Evidence and Impact, McMaster University, Hamilton, Ontario L8S 4K1, Canada
| | - Deborah Yamamura
- Department of Pathology and Molecular Medicine, McMaster University, Hamilton, Ontario L8S 4K1, Canada; Microbiology Department, Hamilton Regional Laboratory Medicine Program, Hamilton Health Sciences, Hamilton, Ontario L8L 2X2, Canada; Division of Infectious Diseases, Department of Medicine, McMaster University, Hamilton, Ontario L8V 1C3, Canada
| | - Cynthia Balion
- Department of Pathology and Molecular Medicine, McMaster University, Hamilton, Ontario L8S 4K1, Canada; Department of Health Research Methods, Evidence and Impact, McMaster University, Hamilton, Ontario L8S 4K1, Canada.
| |
Collapse
|
11
|
Rezaeijo SM, Ghorvei M, Abedi-Firouzjah R, Mojtahedi H, Entezari Zarch H. Detecting COVID-19 in chest images based on deep transfer learning and machine learning algorithms. EGYPTIAN JOURNAL OF RADIOLOGY AND NUCLEAR MEDICINE 2021. [PMCID: PMC8193170 DOI: 10.1186/s43055-021-00524-y] [Citation(s) in RCA: 10] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Indexed: 12/11/2022]
Abstract
Abstract
Background
This study aimed to propose an automatic prediction of COVID-19 disease using chest CT images based on deep transfer learning models and machine learning (ML) algorithms.
Results
The dataset consisted of 5480 samples in two classes, including 2740 CT chest images of patients with confirmed COVID-19 and 2740 images of suspected cases was assessed. The DenseNet201 model has obtained the highest training with an accuracy of 100%. In combining pre-trained models with ML algorithms, the DenseNet201 model and KNN algorithm have received the best performance with an accuracy of 100%. Created map by t-SNE in the DenseNet201 model showed not any points clustered with the wrong class.
Conclusions
The mentioned models can be used in remote places, in low- and middle-income countries, and laboratory equipment with limited resources to overcome a shortage of radiologists.
Collapse
|
12
|
Rabaan AA, Tirupathi R, Sule AA, Aldali J, Mutair AA, Alhumaid S, Muzaheed, Gupta N, Koritala T, Adhikari R, Bilal M, Dhawan M, Tiwari R, Mitra S, Emran TB, Dhama K. Viral Dynamics and Real-Time RT-PCR Ct Values Correlation with Disease Severity in COVID-19. Diagnostics (Basel) 2021; 11:1091. [PMID: 34203738 PMCID: PMC8232180 DOI: 10.3390/diagnostics11061091] [Citation(s) in RCA: 116] [Impact Index Per Article: 38.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/23/2021] [Revised: 06/02/2021] [Accepted: 06/10/2021] [Indexed: 01/08/2023] Open
Abstract
Real-time RT-PCR is considered the gold standard confirmatory test for coronavirus disease 2019 (COVID-19). However, many scientists disagree, and it is essential to understand that several factors and variables can cause a false-negative test. In this context, cycle threshold (Ct) values are being utilized to diagnose or predict SARS-CoV-2 infection. This practice has a significant clinical utility as Ct values can be correlated with the viral load. In addition, Ct values have a strong correlation with multiple haematological and biochemical markers. However, it is essential to consider that Ct values might be affected by pre-analytic, analytic, and post-analytical variables such as collection technique, specimen type, sampling time, viral kinetics, transport and storage conditions, nucleic acid extraction, viral RNA load, primer designing, real-time PCR efficiency, and Ct value determination method. Therefore, understanding the interpretation of Ct values and other influential factors could play a crucial role in interpreting viral load and disease severity. In several clinical studies consisting of small or large sample sizes, several discrepancies exist regarding a significant positive correlation between the Ct value and disease severity in COVID-19. In this context, a revised review of the literature has been conducted to fill the knowledge gaps regarding the correlations between Ct values and severity/fatality rates of patients with COVID-19. Various databases such as PubMed, Science Direct, Medline, Scopus, and Google Scholar were searched up to April 2021 by using keywords including "RT-PCR or viral load", "SARS-CoV-2 and RT-PCR", "Ct value and viral load", "Ct value or COVID-19". Research articles were extracted and selected independently by the authors and included in the present review based on their relevance to the study. The current narrative review explores the correlation of Ct values with mortality, disease progression, severity, and infectivity. We also discuss the factors that can affect these values, such as collection technique, type of swab, sampling method, etc.
Collapse
Affiliation(s)
- Ali A. Rabaan
- Molecular Diagnostic Laboratory, Johns Hopkins Aramco Healthcare, Dhahran 31311, Saudi Arabia;
| | - Raghavendra Tirupathi
- Department of Medicine Keystone Health, Penn State University School of Medicine, Hershey, PA 16801, USA;
- Department of Medicine, Wellspan Chambersburg and Waynesboro Hospitals, Chambersburg, PA 17201, USA
| | - Anupam A Sule
- Department of Informatics and Outcomes, St Joseph Mercy Oakland, Pontiac, MI 48341, USA;
| | - Jehad Aldali
- Pathology Organization, Imam Mohammed Ibn Saud Islamic University, Riyadh 13317, Saudi Arabia;
| | - Abbas Al Mutair
- Research Center, Almoosa Specialist Hospital, Al-Ahsa 36342, Saudi Arabia;
- College of Nursing, Princess Norah Bint Abdulrahman University, Riyadh 11564, Saudi Arabia
- School of Nursing, Wollongong University, Wollongong, NSW 2522, Australia
| | - Saad Alhumaid
- Administration of Pharmaceutical Care, Al-Ahsa Health Cluster, Ministry of Health, Al-Ahsa 31982, Saudi Arabia;
| | - Muzaheed
- Department of Clinical Laboratory Science, College of Applied Medical Sciences, Imam Abdulrahman Bin Faisal University, Dammam 31441, Saudi Arabia;
| | - Nitin Gupta
- Department of Infectious Diseases, Kasturba Medical College, Manipal Academy of Higher Education, Manipal 576104, India;
| | - Thoyaja Koritala
- Department of Internal Medicine, Mayo Clinic Health System Mankato, Mayo Clinic College of Medicine and Science, Mankato, MN 56001, USA;
| | - Ramesh Adhikari
- Department of Hospital Medicine, Franciscan Health Lafayette, Lafayette, IN 47905, USA;
| | - Muhammad Bilal
- School of Life Science and Food Engineering, Huaiyin Institute of Technology, Huaian 223003, China;
| | - Manish Dhawan
- Department of Microbiology, Punjab Agricultural University, Ludhiana 141004, India;
- The Trafford Group of Colleges, Manchester WA14 5PQ, UK
| | - Ruchi Tiwari
- Department of Veterinary Microbiology and Immunology, College of Veterinary Sciences, Uttar Prade Pandit Deen Dayal Upadhyaya Pashu Chikitsa Vigyan Vishwavidyalaya Evam Go Anusandha Sansthan (DUVASU), Mathura 281001, India;
| | - Saikat Mitra
- Department of Pharmacy, Faculty of Pharmacy, University of Dhaka, Dhaka 1000, Bangladesh;
| | - Talha Bin Emran
- Department of Pharmacy, BGC Trust University Bangladesh, Chittagong 4381, Bangladesh
| | - Kuldeep Dhama
- Division of Pathology, ICAR-Indian Veterinary Research Institute, Izatnagar, Bareilly 243122, India
| |
Collapse
|
13
|
Harris DT, Badowski M, Jernigan B, Sprissler R, Edwards T, Cohen R, Paul S, Merchant N, Weinkauf CC, Bime C, Erickson HE, Bixby B, Parthasarathy S, Chaudhary S, Natt B, Cristan E, El Aini T, Rischard F, Campion J, Chopra M, Insel M, Sam A, Knepler JL, Knox K, Mosier J, Spier C, Dake MD. SARS-CoV-2 Rapid Antigen Testing of Symptomatic and Asymptomatic Individuals on the University of Arizona Campus. Biomedicines 2021; 9:539. [PMID: 34066047 PMCID: PMC8150898 DOI: 10.3390/biomedicines9050539] [Citation(s) in RCA: 13] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/12/2021] [Revised: 04/29/2021] [Accepted: 05/05/2021] [Indexed: 01/29/2023] Open
Abstract
SARS-CoV-2, the cause of COVID19, has caused a pandemic that has infected more than 80 M and killed more than 1.6 M persons worldwide. In the US as of December 2020, it has infected more than 32 M people while causing more than 570,000 deaths. As the pandemic persists, there has been a public demand to reopen schools and university campuses. To consider these demands, it is necessary to rapidly identify those individuals infected with the virus and isolate them so that disease transmission can be stopped. In the present study, we examined the sensitivity of the Quidel Rapid Antigen test for use in screening both symptomatic and asymptomatic individuals at the University of Arizona from June to August 2020. A total of 885 symptomatic and 1551 asymptomatic subjects were assessed by antigen testing and real-time PCR testing. The sensitivity of the test for both symptomatic and asymptomatic persons was between 82 and 90%, with some caveats.
Collapse
Affiliation(s)
- David T. Harris
- Biorepository, College of Medicine-Tucson, University of Arizona Health Sciences, University of Arizona, Tucson, AZ 85724, USA; (M.B.); (B.J.)
- Department of Immunobiology & Medicine, College of Medicine-Tucson, University of Arizona Health Sciences, University of Arizona, Tucson, AZ 85724, USA
| | - Michael Badowski
- Biorepository, College of Medicine-Tucson, University of Arizona Health Sciences, University of Arizona, Tucson, AZ 85724, USA; (M.B.); (B.J.)
| | - Brandon Jernigan
- Biorepository, College of Medicine-Tucson, University of Arizona Health Sciences, University of Arizona, Tucson, AZ 85724, USA; (M.B.); (B.J.)
| | - Ryan Sprissler
- College of Medicine-Tucson, University of Arizona Genetics Core, University of Arizona, Tucson, AZ 85724, USA; (R.S.); (T.E.)
| | - Taylor Edwards
- College of Medicine-Tucson, University of Arizona Genetics Core, University of Arizona, Tucson, AZ 85724, USA; (R.S.); (T.E.)
| | - Randall Cohen
- Department of Athletic, University of Arizona, Tucson, AZ 85724, USA; (R.C.); (S.P.)
| | - Stephen Paul
- Department of Athletic, University of Arizona, Tucson, AZ 85724, USA; (R.C.); (S.P.)
| | - Nirav Merchant
- Data Science Institute, University of Arizona, Tucson, AZ 85724, USA;
| | - Craig C. Weinkauf
- Department of Surgery, College of Medicine-Tucson, University of Arizona, Tucson, AZ 85724, USA;
| | - Christian Bime
- Division of Pulmonary, Allergy, Critical Care and Sleep Medicine, College of Medicine-Tucson, University of Arizona, Tucson, AZ 85724, USA; (C.B.); (H.E.E.); (B.B.); (S.P.); (S.C.); (B.N.); (E.C.); (T.E.A.); (F.R.); (J.C.); (M.C.); (M.I.); (A.S.); (J.L.K.)
| | - Heidi E. Erickson
- Division of Pulmonary, Allergy, Critical Care and Sleep Medicine, College of Medicine-Tucson, University of Arizona, Tucson, AZ 85724, USA; (C.B.); (H.E.E.); (B.B.); (S.P.); (S.C.); (B.N.); (E.C.); (T.E.A.); (F.R.); (J.C.); (M.C.); (M.I.); (A.S.); (J.L.K.)
| | - Billie Bixby
- Division of Pulmonary, Allergy, Critical Care and Sleep Medicine, College of Medicine-Tucson, University of Arizona, Tucson, AZ 85724, USA; (C.B.); (H.E.E.); (B.B.); (S.P.); (S.C.); (B.N.); (E.C.); (T.E.A.); (F.R.); (J.C.); (M.C.); (M.I.); (A.S.); (J.L.K.)
| | - Sairam Parthasarathy
- Division of Pulmonary, Allergy, Critical Care and Sleep Medicine, College of Medicine-Tucson, University of Arizona, Tucson, AZ 85724, USA; (C.B.); (H.E.E.); (B.B.); (S.P.); (S.C.); (B.N.); (E.C.); (T.E.A.); (F.R.); (J.C.); (M.C.); (M.I.); (A.S.); (J.L.K.)
| | - Sachin Chaudhary
- Division of Pulmonary, Allergy, Critical Care and Sleep Medicine, College of Medicine-Tucson, University of Arizona, Tucson, AZ 85724, USA; (C.B.); (H.E.E.); (B.B.); (S.P.); (S.C.); (B.N.); (E.C.); (T.E.A.); (F.R.); (J.C.); (M.C.); (M.I.); (A.S.); (J.L.K.)
| | - Bhupinder Natt
- Division of Pulmonary, Allergy, Critical Care and Sleep Medicine, College of Medicine-Tucson, University of Arizona, Tucson, AZ 85724, USA; (C.B.); (H.E.E.); (B.B.); (S.P.); (S.C.); (B.N.); (E.C.); (T.E.A.); (F.R.); (J.C.); (M.C.); (M.I.); (A.S.); (J.L.K.)
| | - Elaine Cristan
- Division of Pulmonary, Allergy, Critical Care and Sleep Medicine, College of Medicine-Tucson, University of Arizona, Tucson, AZ 85724, USA; (C.B.); (H.E.E.); (B.B.); (S.P.); (S.C.); (B.N.); (E.C.); (T.E.A.); (F.R.); (J.C.); (M.C.); (M.I.); (A.S.); (J.L.K.)
| | - Tammer El Aini
- Division of Pulmonary, Allergy, Critical Care and Sleep Medicine, College of Medicine-Tucson, University of Arizona, Tucson, AZ 85724, USA; (C.B.); (H.E.E.); (B.B.); (S.P.); (S.C.); (B.N.); (E.C.); (T.E.A.); (F.R.); (J.C.); (M.C.); (M.I.); (A.S.); (J.L.K.)
| | - Franz Rischard
- Division of Pulmonary, Allergy, Critical Care and Sleep Medicine, College of Medicine-Tucson, University of Arizona, Tucson, AZ 85724, USA; (C.B.); (H.E.E.); (B.B.); (S.P.); (S.C.); (B.N.); (E.C.); (T.E.A.); (F.R.); (J.C.); (M.C.); (M.I.); (A.S.); (J.L.K.)
| | - Janet Campion
- Division of Pulmonary, Allergy, Critical Care and Sleep Medicine, College of Medicine-Tucson, University of Arizona, Tucson, AZ 85724, USA; (C.B.); (H.E.E.); (B.B.); (S.P.); (S.C.); (B.N.); (E.C.); (T.E.A.); (F.R.); (J.C.); (M.C.); (M.I.); (A.S.); (J.L.K.)
| | - Madhav Chopra
- Division of Pulmonary, Allergy, Critical Care and Sleep Medicine, College of Medicine-Tucson, University of Arizona, Tucson, AZ 85724, USA; (C.B.); (H.E.E.); (B.B.); (S.P.); (S.C.); (B.N.); (E.C.); (T.E.A.); (F.R.); (J.C.); (M.C.); (M.I.); (A.S.); (J.L.K.)
| | - Michael Insel
- Division of Pulmonary, Allergy, Critical Care and Sleep Medicine, College of Medicine-Tucson, University of Arizona, Tucson, AZ 85724, USA; (C.B.); (H.E.E.); (B.B.); (S.P.); (S.C.); (B.N.); (E.C.); (T.E.A.); (F.R.); (J.C.); (M.C.); (M.I.); (A.S.); (J.L.K.)
| | - Afshin Sam
- Division of Pulmonary, Allergy, Critical Care and Sleep Medicine, College of Medicine-Tucson, University of Arizona, Tucson, AZ 85724, USA; (C.B.); (H.E.E.); (B.B.); (S.P.); (S.C.); (B.N.); (E.C.); (T.E.A.); (F.R.); (J.C.); (M.C.); (M.I.); (A.S.); (J.L.K.)
| | - James L. Knepler
- Division of Pulmonary, Allergy, Critical Care and Sleep Medicine, College of Medicine-Tucson, University of Arizona, Tucson, AZ 85724, USA; (C.B.); (H.E.E.); (B.B.); (S.P.); (S.C.); (B.N.); (E.C.); (T.E.A.); (F.R.); (J.C.); (M.C.); (M.I.); (A.S.); (J.L.K.)
| | - Kenneth Knox
- Department of Medicine, University of Arizona-Phoenix, Phoenix, AZ 85724, USA;
| | - Jarrod Mosier
- Department of Emergency Medicine, College of Medicine-Tucson, Tucson, AZ 85724, USA;
| | - Catherine Spier
- Department of Pathology, University of Arizona College of Medicine-Tucson, University of Arizona, Tucson, AZ 85724, USA;
| | - Michael D. Dake
- Office of the Senior Vice-President for Health Sciences, University of Arizona, Tucson, AZ 85724, USA;
| |
Collapse
|